China Pharma Holdings
CPHI
5 hedge funds and large institutions have $40.4K invested in China Pharma Holdings in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
216% more capital invested
Capital invested by funds: $12.8K → $40.4K (+$27.7K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more funds holding
Funds holding: 4 → 5 (+1)
0.59% more ownership
Funds ownership: 0.32% → 0.9% (+0.59%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$11K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$9.86K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.82K |
| 4 |
Citigroup
New York
|
+$1.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
-$3.17K |
CPHI Hedge Fund Activity: Q4 2024 in Review
5 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in China Pharma Holdings (CPHI) for Q4 2024, worth a combined $40.4K — up 216% from $12.8K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CPHI positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Two Sigma Securities, adding an estimated $11K. The largest seller was Marex Group, exiting entirely with an estimated $3.17K sold.
- 5 institutional investors held China Pharma Holdings (CPHI) as of Q4 2024, up from 4 in Q3 2024.
- Funds reported $40.4K of China Pharma Holdings stock for Q4 2024, up 216% quarter-over-quarter.
- 2 funds opened new China Pharma Holdings positions in Q4 2024 and 1 closed out, a net change of +1 holder.
- The largest China Pharma Holdings buyer in Q4 2024 was Two Sigma Securities, an estimated $11K added.
- The largest China Pharma Holdings seller in Q4 2024 was Marex Group, an estimated $3.17K sold.
Based on aggregated 13F filings for Q4 2024.